Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Mephisto who wrote (856)	10/22/1999 5:42:00 PM
From: Mephisto	Respond to of 1906

Amgen Names Morstyn Senior Vice President of Development THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 22, 1999--Amgen [AMGN-news] today announced that it has named George Morstyn, MB, MS, Ph.D., Senior Vice President, Development and Chief Medical Officer, succeeding Kirby Alton who is retiring following 18 years at Amgen. Dr. Morstyn previously served as Vice President, Product Development and Chief Medical Officer. "We are extremely fortunate to have someone of George's skills and experience in leading many of Amgen's development programs over the last several years to succeed Kirby, one of Amgen's pioneers," said Gordon Binder, chairman and chief executive officer. "Kirby has done an outstanding job as he presided over the explosive growth in Development from four staff members and five clinical trials in 1986 to more than 1,000 staff members working on 18 product candidates in more than 260 clinical trials today." Dr. Morstyn has been responsible for the design, development and implementation of clinical trials for all product candidates, as well as the submission of clinical data to regulatory authorities and subsequent product approvals. Before he joined Amgen in 1991, Dr. Morstyn conducted clinical and laboratory research at The Ludwig Institute for Cancer Research and at Melbourne University in Australia. Dr. Morstyn trained at the National Cancer Institute in Bethesda, MD and at the Walter and Eliza Hall Institute in Melbourne, Australia. Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology. EDITOR'S NOTE: An electronic version of this news release may be accessed via our web site at www.Amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Amgen News section of the web site. --30--kwp/la* tjj/la CONTACT: Amgen, Thousand Oaks David Kaye, 805/447-6692 (media) Cary Rosansky, 805/447-4634 (investors) Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com (c) 1998 Business Wire